Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754525 | 0.88 | HRH3 (0.32) | LMNAHRH3ALDH1A1CYP1A2 | |
| SCHEMBL25754484 | 0.86 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPTANPEP | |
| SCHEMBL25754504 | 0.83 | HRH3 (0.31) | LMNAHRH3 | |
| SCHEMBL25754478 | 0.78 | LMNA (0.37) | LMNAL3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL25754249 | 0.76 | HRH3 (0.38) | MEN1KMT2AHRH3ALDH1A1MAPT | |
| SCHEMBL25754591 | 0.76 | HRH3 (0.38) | MEN1KMT2AHRH3ALDH1A1MAPT | |
| SCHEMBL25754258 | 0.75 | KDM4E (0.39) | MEN1KMT2AHRH3ALDH1A1MAPT | |
| SCHEMBL28879372 | 0.74 | HRH3 (0.38) | LMNAL3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL25754503 | 0.74 | HRH3 (0.32) | LMNAKMT2AHRH3ALDH1A1TSHR | |
| SCHEMBL25754390 | 0.73 | LMNA (0.35) | LMNAL3MBTL1HRH3MAPTANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | LMNA 1517/4885L3MBTL1 480/4885MEN1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.